
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Lineage, Inc. (LINE) Investors To Inquire About Securities Fraud Class Action
IF YOU SUFFERED A LOSS ON YOUR LINEAGE, INC. (LINE) INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS
What Happened?
In July 2024, Lineage conducted its IPO, selling over 65 million shares of common stock at $78 per share.
On November 6, 2024, Lineage released its third quarter 2024 financial results, revealing that it had suffered a $543 million net loss during the quarter. On this news, Lineage's stock price fell $5.22, or 7.4%, to close at $65.79 per share on November 6, 2024, thereby injuring investors.
Then, on January 14, 2025, The Wall Street Journal reported that Lineage was laying off employees due to reduced customer demand only six months after its IPO.
Then, on April 7, 2025, Lineage announced the dismissal of its auditor, KPMG LLP. On this news, Lineage's stock price fell $5.29, or 9.9%, over two consecutive trading days, to close at $48.41 per share on April 8, 2025.
Then, on April 30, 2025, Lineage reported first quarter 2025 financial results, including that '[t]otal revenue decreased (2.7)%' to $1.29 billion for the quarter. The Company stated it 'experienced more normal seasonal trends in the first quarter after multiple years of elevated inventory levels.' On this news, Lineage's stock price fell $8.16, or 14.62%, to close at $47.65 per share on April 30, 2025, thereby injuring investors further.
On June 3, 2025, the Company stated at an Investor Conference that there has been 'pretty much flat demand' for Lineage's products and services and that the Company was operating in a 'flattish environment' in terms of demand.
The price of Lineage stock has remained substantially below the IPO price at the time of this complaint's filing.
What Is The Lawsuit About?
The complaint filed in this class action alleges that the Registration Statement made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, the Company's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and the Company's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (2) that Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing the Company; (3) that Lineage was unable to effectively counteract the adverse trends listed in the foregoing through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (4) that, as a result of the foregoing, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the Registration Statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired Lineage common pursuant and/or traceable to the IPO, you may move the Court no later than September 30, 2025 to request appointment as lead plaintiff in this putative class action lawsuit.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Call Details: Date: Monday, August 11, 2025 Time: 8:00 AM ET Webcast: Dial-In: 1-877-407-9716 (US), 1-201-493-6779 (International), 13754954 (Conference ID) Virtual/Replay availability: A replay will be archived for 90 days on Compass' Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at Investor Contactir@ ContactAnna Gifford, Chief of Staffmedia@ lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données

Yahoo
5 minutes ago
- Yahoo
How major US stock indexes fared Friday, 8/8/2025
Stocks rose on Wall Street, marking their third winning week in the last four. The S&P 500 rose 0.8% Friday, leaving the index just shy of the record it set last week. The Dow Jones Industrial Average climbed 0.5%, and the Nasdaq added 1% to the record it set a day earlier. Expedia and Gilead Sciences rose sharply after reporting results that easily beat analysts' forecasts. Both companies also raised their outlooks. Asian markets closed mostly lower except in Tokyo, where the Nikkei rose 1.9%. European markets were mixed. Treasury yields rose in the bond market. On Friday: The S&P 500 rose 49.45 points, or 0.8%, to 6,389.45. The Dow Jones Industrial Average rose 206.97 points, or 0.5%, to 44,175.61. The Nasdaq composite rose 207.32 points, or 1%, to 21,450.02. The Russell 2000 index of smaller companies rose 3.70 points, or 0.2%, to 2,218.42. For the week: The S&P 500 is up 151.44 points, or 2.4%. The Dow is up 587.03 points, or 1.3%. The Nasdaq is up 799.89 points, or 3.9%. The Russell 2000 is up 51.64 points, or 2.4%. For the year: The S&P 500 is up 507.82 points, or 8.6%. The Dow is up 1,631.39 points, or 3.8%. The Nasdaq is up 2,139.23 points, or 11.1%. The Russell 2000 is down 11.74 points, or 0.5%. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Meta (META) Downgraded as Growth Is Priced In—But AI Bets Still Impress
Meta Platforms, Inc. (NASDAQ:META) is one of the . On August 6, Freedom Broker analyst Saken Ismailov downgraded the stock from Buy to Hold with a price target of $800.00 (from $680.00). The firm has acknowledged how Meta has outperformed the most optimistic of expectations for key performance indicators in Q2 2025. Factors driving this impressive performance include advertising pricing recovery, heightened user engagement, and widespread adoption of AI tools. It further pointed out Meta's raised revenue guidance and upward revision of its full-year capEx expectations, highlighting strategic focus on building proprietary AI infrastructure. A scientist at a computer station, surrounded by a neural network of artificial intelligence code. However, stronger revenue growth isn't the only thing these investments will be driving, the firm noted. 'While these investments are poised to drive stronger revenue growth in 2026, they also result in increased depreciation, amortization, and compensation expenses, which may temper profitability growth. Another catalyst for future revenue growth is the anticipated debut of advertising formats within WhatsApp. We maintain a positive outlook on Meta's performance and elevate our price target from $680 to $800. Nevertheless, we're adjusting our recommendation from 'Buy' to 'Hold,' as the current premium valuation multiples already encapsulate the anticipated growth rate in the company's earnings.' While we acknowledge the potential of META as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio